Equifax Inc. (EFX) Stock Forecast
Data as of Jun 16, 2026Industrials · Current price $166.79 (+0.97%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 5, 2026 | Ashish Sabadra | RBC Capital | $222.00 | +33.1% |
| Feb 5, 2026 | Manav Patnaik | Barclays | $215.00 | +28.9% |
| Feb 4, 2026 | Toni Kaplan | Morgan Stanley | $244.00 | +46.3% |
| Jul 23, 2025 | Kevin McVeigh | UBS | $278.00 | +66.7% |
| Jun 23, 2025 | Joshua Dennerlein | Bank of America Securities | $285.00 | +70.9% |
| Mar 20, 2025 | Ashish Sabadra | RBC Capital | $300.00 | +79.9% |
| Dec 16, 2024 | Andrew Grobler | BNP Paribas | $305.00 | +82.9% |
| Oct 11, 2024 | Arthur Truslove | Citigroup | $331.00 | +98.5% |
| Sep 19, 2024 | Andrew Grobler | BNP Paribas | $310.00 | +85.9% |
| Sep 13, 2024 | Manav Patnaik | Barclays | $380.00 | +127.8% |
| Sep 12, 2024 | Toni Kaplan | New Street | $271.00 | +62.5% |
| Aug 28, 2024 | Kyle Peterson | Needham | $350.00 | +109.8% |
| Aug 12, 2024 | Jason Haas | Wells Fargo | $340.00 | +103.8% |
| Jul 19, 2024 | Kyle Peterson | Needham | $320.00 | +91.9% |
| Jul 19, 2024 | Shlomo Rosenbaum | Stifel Nicolaus | $305.00 | +82.9% |
| Jul 19, 2024 | Owen Lau | Oppenheimer | $300.00 | +79.9% |
| Jul 18, 2024 | George Tong | Goldman Sachs | $277.00 | +66.1% |
| Jul 18, 2024 | David Togut | Evercore ISI | $305.00 | +82.9% |
| Apr 19, 2024 | Owen Lau | Oppenheimer | $272.00 | +63.1% |
| Apr 19, 2024 | Shlomo Rosenbaum | Stifel Nicolaus | $265.00 | +58.9% |
Top Analysts Covering EFX
EFX vs Sector & Market
| Metric | EFX | Industrials Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.12 | 2.41 | 2.40 |
| Analyst Count | 17 | 8 | 19 |
| Target Upside | +40.0% | +88.5% | +17.1% |
| P/E Ratio | 29.36 | 26.79 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $6.70B | $6.75B | $6.80B | 20 |
| 2027-03-31 | $1.77B | $1.79B | $1.82B | 9 |
| 2027-06-30 | $1.84B | $1.86B | $1.89B | 9 |
| 2027-09-30 | $1.85B | $1.87B | $1.90B | 14 |
| 2027-12-31 | $1.84B | $1.86B | $1.89B | 9 |
| 2028-03-31 | $1.90B | $1.92B | $1.95B | 8 |
| 2028-06-30 | $1.97B | $1.99B | $2.03B | 11 |
| 2028-09-30 | $1.98B | $2.00B | $2.04B | 8 |
| 2028-12-31 | $1.98B | $2.00B | $2.03B | 8 |
| 2029-12-31 | $8.37B | $8.58B | $8.92B | 9 |
| 2030-12-31 | $8.61B | $8.82B | $9.18B | 13 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $8.32 | $8.61 | $9.68 | 19 |
| 2027-03-31 | $2.13 | $2.16 | $2.21 | 9 |
| 2027-06-30 | $2.60 | $2.63 | $2.69 | 8 |
| 2027-09-30 | $2.65 | $2.68 | $2.75 | 8 |
| 2027-12-31 | $2.71 | $2.74 | $2.81 | 16 |
| 2028-03-31 | $2.45 | $2.48 | $2.54 | 16 |
| 2028-06-30 | $2.95 | $2.99 | $3.06 | 11 |
| 2028-09-30 | $3.02 | $3.06 | $3.13 | 9 |
| 2028-12-31 | $3.08 | $3.12 | $3.20 | 9 |
| 2029-12-31 | $14.57 | $15.05 | $15.84 | 4 |
| 2030-12-31 | $16.43 | $16.97 | $17.86 | 2 |
Frequently Asked Questions
What is the analyst consensus for EFX?
The consensus among 17 analysts covering Equifax Inc. (EFX) is Buy with an average price target of $238.18.
What is the highest price target for EFX?
The highest price target for EFX is $380.00, set by Manav Patnaik at Barclays on 2024-09-13.
What is the lowest price target for EFX?
The lowest price target for EFX is $200.00, set by David Togut at Evercore ISI on 2022-04-29.
How many analysts cover EFX?
17 analysts have issued ratings for Equifax Inc. in the past 12 months.
Is EFX a buy or sell right now?
Based on 17 analyst ratings, EFX has a consensus rating of Buy (2.12/5) with a +40.0% upside to the consensus target of $238.18.
What are the earnings estimates for EFX?
Analysts estimate EFX will report EPS of $8.61 for the period ending 2026-12-31, with revenue estimated at $6.75B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.